RhumbLine Advisers’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $716K | Sell |
59,783
-704
| -1% | -$5.84K | ﹤0.01% | 2529 |
|
|
2026
Q1 | $507K | Sell |
60,487
-5,338
| -8% | -$56.1K | ﹤0.01% | 2603 |
|
|
2025
Q4 | $948K | Sell |
65,825
-7,199
| -10% | -$89.7K | ﹤0.01% | 2255 |
|
|
2025
Q3 | $705K | Buy |
73,024
+874
| +1% | +$7.73K | ﹤0.01% | 2462 |
|
|
2025
Q2 | $592K | Buy |
72,150
+995
| +1% | +$8.33K | ﹤0.01% | 2577 |
|
|
2025
Q1 | $509K | Sell |
71,155
-3,114
| -4% | -$23.2K | ﹤0.01% | 2568 |
|
|
2024
Q4 | $574K | Sell |
74,269
-40,756
| -35% | -$383K | ﹤0.01% | 2588 |
|
|
2024
Q3 | $1.21M | Sell |
115,025
-3,501
| -3% | -$42.7K | ﹤0.01% | 2165 |
|
|
2024
Q2 | $1.39M | Buy |
118,526
+8,987
| +8% | +$140K | ﹤0.01% | 2071 |
|
|
2024
Q1 | $2.31M | Sell |
109,539
-1,792
| -2% | -$31.9K | ﹤0.01% | 1836 |
|
|
2023
Q4 | $2M | Buy |
111,331
+4,697
| +4% | +$82.7K | ﹤0.01% | 1906 |
|
|
2023
Q3 | $1.76M | Buy |
106,634
+1,512
| +1% | +$27.4K | ﹤0.01% | 1917 |
|
|
2023
Q2 | $2.1M | Buy |
105,122
+1,976
| +2% | +$38.1K | ﹤0.01% | 1876 |
|
|
2023
Q1 | $1.95M | Buy |
103,146
+3,364
| +3% | +$74.4K | ﹤0.01% | 1815 |
|
|
2022
Q4 | $2.26M | Sell |
99,782
-3,898
| -4% | -$88.1K | ﹤0.01% | 1716 |
|
|
2022
Q3 | $2.74M | Buy |
103,680
+6,325
| +6% | +$188K | ﹤0.01% | 1601 |
|
|
2022
Q2 | $2.4M | Buy |
97,355
+9,928
| +11% | +$248K | ﹤0.01% | 1674 |
|
|
2022
Q1 | $2.9M | Buy |
87,427
+5,443
| +7% | +$151K | ﹤0.01% | 1614 |
|
|
2021
Q4 | $2.68M | Sell |
81,984
-2,163
| -3% | -$73.7K | ﹤0.01% | 1725 |
|
|
2021
Q3 | $3.53M | Sell |
84,147
-8,634
| -9% | -$311K | ﹤0.01% | 1568 |
|
|
2021
Q2 | $3.6M | Buy |
92,781
+11,769
| +15% | +$421K | ﹤0.01% | 1623 |
|
|
2021
Q1 | $2.76M | Buy |
81,012
+9,433
| +13% | +$402K | ﹤0.01% | 1750 |
|
|
2020
Q4 | $3.25M | Sell |
71,579
-4,379
| -6% | -$153K | ﹤0.01% | 1601 |
|
|
2020
Q3 | $2.09M | Sell |
75,958
-10,648
| -12% | -$347K | ﹤0.01% | 1661 |
|
|
2020
Q2 | $3.19M | Sell |
86,606
-5,124
| -6% | -$191K | 0.01% | 1458 |
|
|
2020
Q1 | $2.97M | Buy |
91,730
+2,796
| +3% | +$116K | 0.01% | 1335 |
|
|
2019
Q4 | $3.64M | Buy |
88,934
+9,452
| +12% | +$373K | 0.01% | 1449 |
|
|
2019
Q3 | $2.83M | Sell |
79,482
-480
| -0.6% | -$19.4K | 0.01% | 1533 |
|
|
2019
Q2 | $4.11M | Buy |
79,962
+6,953
| +10% | +$347K | 0.01% | 1309 |
|
|
2019
Q1 | $4.18M | Sell |
73,009
-800
| -1% | -$39.6K | 0.01% | 1283 |
|
|
2018
Q4 | $3.1M | Buy |
73,809
+17,557
| +31% | +$1.03M | 0.01% | 1383 |
|
|
2018
Q3 | $4.25M | Sell |
56,252
-86
| -0.2% | -$6.2K | 0.01% | 1216 |
|
|
2018
Q2 | $4.04M | Buy |
56,338
+29,002
| +106% | +$1.39M | 0.01% | 1252 |
|
|
2018
Q1 | $816K | Sell |
27,336
-315
| -1% | -$9.17K | ﹤0.01% | 2032 |
|
|
2017
Q4 | $919K | Hold |
27,651
| – | – | ﹤0.01% | 1988 |
|
|
2017
Q3 | $911K | Buy |
27,651
+400
| +1% | +$9K | ﹤0.01% | 2023 |
|
|
2017
Q2 | $538K | Buy |
27,251
+8,520
| +45% | +$165K | ﹤0.01% | 2252 |
|
|
2017
Q1 | $362K | Buy |
18,731
+998
| +6% | +$19.2K | ﹤0.01% | 2409 |
|
|
2016
Q4 | $329K | Sell |
17,733
-2,125
| -11% | -$40.6K | ﹤0.01% | 2445 |
|
|
2016
Q3 | $278K | Buy |
19,858
+1,350
| +7% | +$14.9K | ﹤0.01% | 2522 |
|
|
2016
Q2 | $148K | Buy |
+18,508
| New | +$205K | ﹤0.01% | 2835 |
|
Other funds holding RGNX
RG
RhumbLine Advisers's RGNX Position: Q2 2026 in Review
RhumbLine Advisers reduced its Regenxbio (RGNX) stake by 1.2% in Q2 2026, selling an estimated $5.84K and leaving 59,783 shares worth $716K. The position accounts for ﹤0.01% of the portfolio, ranked #2529.
RhumbLine Advisers first reported a position in RGNX in Q2 2016 and has held it in 41 quarters since. The position peaked at $4.25M in Q3 2018. 165 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.
- RhumbLine Advisers held 59,783 shares of Regenxbio worth $716K as of Q2 2026.
- RhumbLine Advisers sold 704 Regenxbio shares in Q2 2026, an estimated $5.84K.
- Regenxbio made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2529 holding.
- RhumbLine Advisers first reported a position in Regenxbio in Q2 2016 and has held it in 41 quarters since.
- RhumbLine Advisers's Regenxbio position peaked at $4.25M in Q3 2018.
- 165 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.